Detalhe da pesquisa
1.
Changes in HER3 expression profiles between primary and recurrent gynecological cancers.
Cancer Cell Int
; 23(1): 18, 2023 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737733
2.
Comprehensive screening for drugs that modify radiation-induced immune responses.
Br J Cancer
; 126(12): 1815-1823, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184156
3.
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
Oncology
; 100(7): 370-375, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405680
4.
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.
Cancer Sci
; 109(1): 207-214, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29114963
5.
Trends in the development of MET inhibitors for hepatocellular carcinoma.
Future Oncol
; 12(10): 1275-86, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26984595
6.
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
Anticancer Res
; 44(5): 2125-2132, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38677749
7.
Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping.
Diagnostics (Basel)
; 13(12)2023 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37370935
8.
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Clin Cancer Res
; 29(24): 5079-5086, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37819940
9.
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma.
Gynecol Oncol Rep
; 50: 101302, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38054200
10.
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.
Cancers (Basel)
; 14(10)2022 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35626060
11.
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036223
12.
MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial.
Clin Pharmacol Ther
; 108(3): 596-605, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32112563
13.
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.
Oncol Lett
; 20(4): 38, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32802162
14.
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer.
Oncol Lett
; 20(6): 336, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33123247
15.
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.
Clin Pharmacol Ther
; 106(4): 803-809, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30927439
16.
Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project.
Clin Pharmacol Ther
; 106(3): 491-492, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121054